Synonym
Metamelfalan; m-L-Sarcolysin; Metamelfalanum; NSC 67781; NSC67781; NSC-67781;
IUPAC/Chemical Name
(S)-2-amino-3-(3-(bis(2-chloroethyl)amino)phenyl)propanoic acid
InChi Key
QDGAVODICPCDMU-LBPRGKRZSA-N
InChi Code
InChI=1S/C13H18Cl2N2O2/c14-4-6-17(7-5-15)11-3-1-2-10(8-11)9-12(16)13(18)19/h1-3,8,12H,4-7,9,16H2,(H,18,19)/t12-/m0/s1
SMILES Code
N[C@@H](CC1=CC=CC(N(CCCl)CCCl)=C1)C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
305.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Mol Cancer Ther. 2003 Dec;2(12):1331-9. PubMed PMID: 14707274.
2: Jiang JD, Zhang H, Li JN, Roboz J, Qiao WB, Holland JF, Bekesi G. High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo. Anticancer Res. 2001 May-Jun;21(3B):1681-9. PubMed PMID: 11497247.
3: Larsson R, Dhar S, Ehrsson H, Nygren P, Lewensohn R. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients. Br J Cancer. 1998 Aug;78(3):328-35. PubMed PMID: 9703278; PubMed Central PMCID: PMC2063025.
4: Hansson J, Lewensohn R, Ringborg U. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Anticancer Res. 1991 Sep-Oct;11(5):1725-30. PubMed PMID: 1768043.
5: Lewensohn R, Ehrsson H, Hansson J, Ringborg U. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Anticancer Res. 1991 Jan-Feb;11(1):321-4. PubMed PMID: 2018366.
6: Lewensohn R, Hansson J, Ringborg U, Ehrsson H. Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio. Eur J Cancer Clin Oncol. 1987 Jun;23(6):783-8. PubMed PMID: 3653195.
